Patient-specific modelling of regional tobramycin concentration levels in airways of patients with cystic fibrosis: can we dose once daily? | Zendy

Aukje C. Bos | Zendy; Johan W. Mouton | Zendy; Mireille van Westreenen | Zendy; EleniRosalina Andrinopoulou | Zendy; Hettie M. Janssens | Zendy; Harm A.W.M. Tiddens | Zendy

Open Access

Patient-specific modelling of regional tobramycin concentration levels in airways of patients with cystic fibrosis: can we dose once daily?

Author(s) -

Aukje C. Bos,

Johan W. Mouton,

Mireille van Westreenen,

EleniRosalina Andrinopoulou,

Hettie M. Janssens,

Harm A.W.M. Tiddens

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx293

Subject(s) - tobramycin , cystic fibrosis , medicine , antibiotics , intensive care medicine , microbiology and biotechnology , biology , gentamicin

Inhaled tobramycin is important in the treatment of Pseudomonas aeruginosa (Pa) infections in cystic fibrosis (CF). However, despite its use it fails to attenuate the clinical progression of CF lung disease. The bactericidal efficacy of tobramycin is known to be concentration-dependent and hence changing the dosing regimen from a twice-daily (q12h) inhalation to a once-daily (q24h) inhaled double dose could improve treatment outcomes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research